Washington desperately needs a win: How about paid family leave?

We have had Governors, business leaders, Members of Congress, Presidential candidates and Administrations from both parties call for paid family leave but it still can not break through in Washington. Just this past month, in true bipartisan fashion, AEI and Brookings...
Returning From Recess: What We’ve Learned

Returning From Recess: What We’ve Learned

As the current administration touts an agenda that is “Achieving Results for the American People,” Congressional recesses are shaping up to be the prime forum for constituents to check in with their elected officials to see what type of progress they actually feel and...

21st Century Cures Act: Success in a Lame Duck Session

Derrick M. White Senior Vice President As the President signs the 21st Century Cures Act into law today – we’re reminded that every once in a while, Congress can be productive during a Lame Duck session. While heavily debated, and stuck for months, the bill ultimately...
Derrick M. White
Senior Vice President

Derrick White, a Senior Vice President at Forbes Tate Partners, joined the firm in October 2015.

From April 1996 until July 2001, Mr. White served on the state, DC, and Judiciary Committee staffs of U.S. Senator Orrin Hatch (R-UT), current Chairman of the Senate Finance Committee and senior member of the Senate Health Education Labor and Pensions (HELP) Committee and Senate Judiciary Committee. While with Chairman Hatch, Derrick covered issues in healthcare, defense and trade.

At the time of his departure from Senator Hatch’s staff, Derrick was serving as Deputy Communications Director.

From July 2001 to January 2009, Mr. White was a member of the Federal Government Relations team at the Pharmaceutical Research and Manufacturers of America (PhRMA). In his capacity at PhRMA, Mr. White worked on a broad range of issues, including: Medicare, Medicaid, the Prescription Drug User Fee Act (PDUFA) III, and IV (FDAAA), the Project Bioshield Act of 2004, 340B, Bioterrorism, patents, and vaccines.

Mr. White also played a crucial role in working with Congress to craft and pass the landmark Medicare Modernization Act of 2003 – which created the current prescription drug Part D benefit for seniors.

Upon leaving PhRMA, Derrick operated as an independent consultant and continued to advise and represent PhRMA on the legislative deliberations on both the Affordable Care Act of 2009 and the America Invents Act of 2011.

From 2012 until joining Forbes Tate Partners in 2015, Mr. White was a member of the Federal Government Relations team at the Biotechnology Innovation Organization (BIO). At BIO, Mr. White led the organization’s engagement with Republican Senators and their staffs and Committee staffs.

Derrick also played a central role in BIO’s efforts on the Prescription Drug User Fee Act reauthorization (PDUFA V) via the Food and Drug Safety and Innovation Act (FDASIA), the Drug Quality and Security Act, patent reform, 340B, and vaccines.

At the time of his departure from BIO, Mr. White was engaged in BIO’s efforts on the Senate HELP Committee’s forthcoming 21st Century Cures legislation, negotiations with the Senate Judiciary Committee on pending patent reform legislation, and preparations for the upcoming activities associated with the reauthorization of PDUFA (PDUFA VI).

Mr. White, a lifelong Republican, has been active in the Party and campaigns since college. He worked on Senator Hatch’s past three campaigns (2000, 2006 and 2012) – and also participated in the NRSC Special Teams program for Senators Thune (2004), Burns (2006), and Toomey’s (2010) races.

A native of Towanda, Pennsylvania and a graduate of the University of Utah, Derrick received his Bachelor’s degree in Political Science and International Relations.